Rx Item-Glyburide 2.5MG 1000 Tab by Teva Pharma USA

GLYBURIDE - glyburide tablet
Aurobindo Pharma Limited

DESCRIPTION

Glyburide is an oral blood-glucose-lowering drug of the sulfonylurea class. Glyburide USP is a white, crystalline compound, formulated as glyburide tablets of 1.25, 2.5, and 5 mg strengths for oral administration. Inactive ingredients: dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, sodium alginate, and talc. The chemical name for glyburide is 1-[[p-[2-(5-chloro-o-anisamido)-ethyl]phenyl]-sulfonyl]-3-cyclohexylurea and the molecular weight is 493.99
CLINICAL PHARMACOLOGY




Actions
Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms.
INDICATIONS AND USAGE

Glyburide tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DOSAGE AND ADMINISTRATION



Patients should be retitrated when transferred from micronized glyburide tablets or other oral hypoglycemic agents. (See PRECAUTIONS).
There is no fixed dosage regimen for the management of diabetes mellitus with glyburide tablets. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e. , loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.Short-term administration of glyburide may be sufficient during periods of transient loss of control in patients usually controlled well on diet.

Rx Item-Glyburide 2.5MG 1000 Tab by Teva
Item No. RX463240, 463240, NDC No.: 00093-8343-10, 00093-343-10, 0009334310, 00093834310, 8343-10, 834310 UPC No. 3-00938-34310-2, 300938-343102, 300938343102

Rx Item-Glyburide 2.5MG 1000 Tab by Teva
Item No. RX463240, 463240, NDC No.: 00093-8343-10, 00093-343-10, 0009334310, 00093834310, 8343-10, 834310 UPC No. 3-00938-34310-2, 300938-343102, 300938343102

Rx Item-Glyburide 2.5MG 1000 Tab by Teva
Rx items can only be ordered by a valid licence holder in scope of practice by-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physica